Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, Martin Schüler, Aaron S. Mansfield, Giuseppe Curigliano, Marcia S. Brose, Viola W. Zhu, Sophie Leboulleux, Daniel W. Bowles, Christina S. Baik, Douglas Adkins, Bhumsuk Keam, Ignacio Matos, Elena Garralda, Justin F. Gainor, Gilberto Lopes, Chia‐Chi Lin, Yann Godbert, Debashis Sarker, Stephen G. Miller, Corinne Clifford, Hui Zhang, Christopher D. Turner, Matthew H. Taylor